Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Vistagen Therapeutics, Inc.
Vistagen Announces Pricing of $100 Million Underwritten Offering
October 02, 2023
From
Vistagen Therapeutics, Inc.
Via
Business Wire
Tickers
VTGN
Vistagen Announces Results of Voting from 2022 Annual Meeting of Stockholders and Partial Adjournment to October 28, 2022
October 19, 2022
From
Vistagen Therapeutics, Inc.
Via
Business Wire
Tickers
VTGN
Vistagen Announces the Two Leading Proxy Advisory Firms, Institutional Shareholder Services and Glass Lewis, Recommend Stockholders Vote “FOR” Proposal No. 5 to Provide its Board with the Option to Implement a Future Reverse Stock Split, if Necessary
October 06, 2022
From
Vistagen Therapeutics, Inc.
Via
Business Wire
Tickers
VTGN
Vistagen to Participate in Upcoming Morgan Stanley and Baird Healthcare Conferences
September 09, 2022
From
Vistagen Therapeutics, Inc.
Via
Business Wire
Tickers
VTGN
Vistagen to Proceed with PALISADE-2 Phase 3 Clinical Trial of PH94B in Social Anxiety Disorder following Interim Analysis
September 08, 2022
From
Vistagen Therapeutics, Inc.
Via
Business Wire
Tickers
VTGN
VistaGen Therapeutics Reports First Quarter Financial Results and Provides Corporate Update
August 11, 2022
From
VistaGen Therapeutics, Inc.
Via
Business Wire
Tickers
VTGN
VistaGen Announces Topline Results from PALISADE-1 Phase 3 Clinical Trial for Investigational Drug PH94B
July 22, 2022
From
VistaGen Therapeutics, Inc.
Via
Business Wire
Tickers
VTGN
VistaGen CEO Joins U.S. Surgeon General to Discuss Mental Health Crisis in America at the 2022 Concordia Americas Summit
July 12, 2022
From
VistaGen Therapeutics, Inc.
Via
Business Wire
Tickers
VTGN
VistaGen to Participate at William Blair Biotech Focus Conference 2022
July 07, 2022
From
VistaGen Therapeutics, Inc.
Via
Business Wire
Tickers
VTGN
VistaGen Therapeutics Reports Fiscal Year 2022 Financial Results and Provides Corporate Update
June 23, 2022
From
VistaGen Therapeutics, Inc.
Via
Business Wire
Tickers
VTGN
VistaGen Announces Completion of PALISADE-1 Phase 3 Clinical Study of PH94B for the Acute Treatment of Social Anxiety Disorder
June 22, 2022
From
VistaGen Therapeutics, Inc.
Via
Business Wire
Tickers
VTGN
VistaGen Therapeutics to Report Fiscal Year 2022 Financial Results on June 23, 2022
June 17, 2022
From
VistaGen Therapeutics, Inc.
Via
Business Wire
Tickers
VTGN
VistaGen to Present PH94B Exploratory Phase 2A Research Program for Adjustment Disorder with Anxiety at American Society for Clinical Psychopharmacology Annual Meeting
June 02, 2022
From
VistaGen Therapeutics, Inc.
Via
Business Wire
Tickers
VTGN
VistaGen to Participate in Upcoming June Investor Conferences
May 27, 2022
From
VistaGen Therapeutics, Inc.
Via
Business Wire
Tickers
VTGN
VistaGen Announces Key Regulatory Update on PH94B for the Acute Treatment of Social Anxiety Disorder
May 05, 2022
From
VistaGen Therapeutics, Inc.
Via
Business Wire
VistaGen Appoints Reid Adler as Chief Legal Officer
May 02, 2022
From
VistaGen Therapeutics, Inc.
Via
Business Wire
Tickers
VTGN
VistaGen to Present Preclinical Data on Lead Candidate PH94B at Upcoming Scientific Congresses
April 21, 2022
From
VistaGen Therapeutics, Inc.
Via
Business Wire
Tickers
VTGN
VistaGen and AffaMed Complete Key Regulatory Submissions for PALISADE Global Phase 3 Clinical Trial for PH94B
April 12, 2022
From
VistaGen Therapeutics, Inc.
Via
Business Wire
Tickers
VTGN
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.